Zurich Cantonal Bank
PHAT icon

Zurich Cantonal Bank’s Phathom Pharmaceuticals PHAT Stock Holding History

Zurich Cantonal Bank’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$280K Buy
25,838
+846
+3% +$9.65K ﹤0.01% 2214
2026
Q1 		$278K Buy
+24,992
New +$316K ﹤0.01% 2133
2025
Q2 		– Sell
-15,710
Closed -$98.5K – 2617
2025
Q1 		$98.5K Hold
15,710
– – ﹤0.01% 2394
2024
Q4 		$128K Buy
15,710
+5,639
+56% +$69.8K ﹤0.01% 2345
2024
Q3 		$182K Hold
10,071
– – ﹤0.01% 2162
2024
Q2 		$104K Buy
10,071
+2,987
+42% +$30.8K ﹤0.01% 2360
2024
Q1 		$75.2K Sell
7,084
-1,187
-14% -$10.1K ﹤0.01% 2477
2023
Q4 		$75.5K Sell
8,271
-158
-2% -$1.36K ﹤0.01% 2531
2023
Q3 		$87.4K Buy
8,429
+6,641
+371% +$91.1K ﹤0.01% 2418
2023
Q2 		$25.6K Sell
1,788
-353
-16% -$4.07K ﹤0.01% 2700
2023
Q1 		$15.3K Buy
+2,141
New +$18.8K ﹤0.01% 2782

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Zurich Cantonal Bank's PHAT Position: Q2 2026 in Review

Zurich Cantonal Bank increased its Phathom Pharmaceuticals (PHAT) stake by 3.4% in Q2 2026, buying an estimated $9.65K and bringing the position to 25,838 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #2214.

Zurich Cantonal Bank first reported a position in PHAT in Q1 2023 and has held it in 11 quarters since. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Zurich Cantonal Bank held 25,838 shares of Phathom Pharmaceuticals worth $280K as of Q2 2026.
  • Zurich Cantonal Bank bought 846 Phathom Pharmaceuticals shares in Q2 2026, an estimated $9.65K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Zurich Cantonal Bank's portfolio in Q2 2026, its #2214 holding.
  • Zurich Cantonal Bank first reported a position in Phathom Pharmaceuticals in Q1 2023 and has held it in 11 quarters since.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Zurich Cantonal Bank's 13F filing for Q2 2026, filed 12 Aug 2026.